Skip to main content
Year archive

THERACRYF PLC — 2023 filings

All 23 regulatory filings released by THERACRYF PLC (TCF) in 2023, sourced directly from the official regulator.

23 Filings
2023 Period
2023 filings (23)
Filing Released Lang
Holding(s) in Company
Major Shareholding Notification
2023-12-29 English
Directorate Changes
Board/Management Information
2023-12-22 English
Upcoming conferences
Report Publication Announcement
2023-11-13 English
Half-year Report
Interim / Quarterly Report H1 2023
2023-10-31 English
Erasmus Medical Center begins glioblastoma studies
Regulatory Filings
2023-10-26 English
Authored Article Publication
Report Publication Announcement
2023-10-19 English
Directorate Changes
Board/Management Information
2023-09-05 English
Final Report from Phase 1b PK/PD study
Regulatory Filings
2023-08-15 English
Rule 17 Disclosure
Legal Proceedings Report
2023-08-03 English
Return of rights to Sulforadex from Juvenescence
Regulatory Filings
2023-08-02 English
Result of AGM
AGM Information
2023-07-21 English
SFX-01 radiosensitisation effect confirmed in-vivo
Regulatory Filings
2023-06-27 English
Notice of AGM & Posting of Annual Report
AGM Information
2023-06-20 English
Grant Success for Glioblastoma studies
Regulatory Filings
2023-06-19 English
Final Results
Annual Report FY 2023
2023-06-07 English
Notice of Results
Report Publication Announcement
2023-05-26 English
Preliminary results from Phase 1b study
Regulatory Filings
2023-03-22 English
Price Monitoring Extension
Regulatory Filings
2023-03-16 English
Second Price Monitoring Extn
Regulatory Filings
2023-03-16 English
Price Monitoring Extension
Regulatory Filings
2023-03-16 English
Further evidence of radiosensitisation by SFX-01
Environmental & Social Information
2023-03-16 English
No exposure to Silicon Valley Bank
Regulatory Filings
2023-03-13 English
Clinical trial update
Regulatory Filings
2023-01-25 English